spokespersons for Modern and your legal representative in Mexico, Asofarmareported that it is expected that next Friday, December 15, the first shipment of their vaccine against covid-19, which will be marketed through public and private health institutions.
“From this moment on we can take orders from all public and private institutions that request it,” said the General Director of Asofarma México, Fonken Quiroga, at a press conference.
Just yesterday, the Federal Commission for the Protection against Health Risks (Cofepris) granted health registration to the vaccines against Covid-19, Spikevax, from Moderna, and Comirnaty, from Pfizer
“At this moment we have quite advanced agreements with some public and some private institutions, which means that in the following days the first shipment of vaccines should be arriving and they will be available through these institutions (…) tens of thousands of vaccines in that first shipment,” he explained.
Among the negotiators are 10 of the country’s 32 states, both with public and private institutions, which are the ones that will deliver the vaccine to citizens.
Permissions
However, he clarified that given the recent announcement some aspects are still being defined.
Fonken Quiroga indicated that the Mexican Government maintains the exemption of vaccine import permits, which he celebrated by pointing out that otherwise, the process could take almost two months.
Regarding the price, he said that it has not yet been defined because they are still agreeing on it in dialogues with public and private institutions in the country.
“Very soon, once all these agreements are closed, we will be able to convey the final price to you. It is important to highlight that the vaccine is a fundamental tool that allows us to protect ourselves from serious illnesses, hospitalization and eventually death, therefore, the The value that the vaccine provides is high and the price will be related to the value that the vaccine offers,” he said.
The general director of Asofarma Mexico recalled that this vaccine requires maintaining a certain temperature and a specific logistics for your transportationwhich he asserted, is guaranteed.
“The logistics network is very important, because the vaccine comes frozen and has to be transported that way, then it is thawed and marketed, distributed in a cold network. This logistics is demanding and we are able to offer extremely robust and ensure full guarantee of the appropriate temperature to maintain the vaccine,” he assured.
Features and candidates
This vaccine against Covid-19 Moderna’s update for active immunization to prevent disease caused by SARS-CoV-2 is aimed at people six months of age and older.
Rolando Pajón, one of the developers of the mRNA platform and a member of the Moderna team that developed the vaccine against Covid-19highlighted that data from the clinical research trial showed that it provokes an immune response in humans through multiple circulating variants, including XBB.1.5, XBB.1.16, XBB.2.3.2, EG.5, FL.1.5.1, and BA.2.86.
He clarified that because this latest generation of vaccines from said pharmaceutical company is being introduced in Mexico, there is no hard data on its effectiveness in the country, but he reported that it is expected to be similar to the previous version that offered 77 percent against symptomatic disease and 88 percent in case of hospitalization or death.
“Real-world data still needs to be generated to be able to give it a number associated with its effectiveness, but hopefully it will be as high as what we have seen in the past, and it is very likely that it will again be the highest in the group of vaccines available,” he said.
Clinical studies
Pajón pointed out that 11 months have passed since the virus genome was published, the clinical studies were completed, emergency use authorization was obtained and the application of the vaccine began, highlighting their speed in developing the biological and maintaining that they are in ability to update the vaccine every three months “if necessary.”
At a press conference it was clarified that this vaccine can be applied at the same time as the influenza vaccine, and the adverse effects are those known as headache and pain in the arm, but they recommended that those who presented serious effects in the past applications do not access it. they.
They announced that by 2025 they hope to have a vaccine that combines protection against Covid-19 and influenza.
Moderna has received authorizations for the vaccine against Covid-19 updated in various countries, including the United States and the European Union, generating great expectation and demand in the different territories where it has been approved.
Route to market
April 2023, approval of registration for the Emergency Use of the monovalent vaccine of the Ancestral strain with indication from 18 years of age. October 17, 2023, Opinion of the Committee on New Molecules for the updated monovalent vaccine XBB.1.56 of November 2023: Submission of Dossier to Cofepris of updated monovalent vaccine XBB.1.5 December 7, 2023: Approval of the health registry
2023-12-08 21:55:00
#Moderna #vaccines #sale #arrive #week #EXPRESO
